Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / news releases / BIOVF - Selecta Biosciences Is A Buy After Major Deal


BIOVF - Selecta Biosciences Is A Buy After Major Deal

This past Friday, Selecta Biosciences (SELB) announced a large deal with Swedish Orphan Biovitrum AB [Sobi] (OTCPK:BIOVF) worth a possible $730M plus double-digit royalties, with $100M of that upfront.

That's quite a large sum for a company that has a current market cap of $234M. Let's look at how this deal changes the investment thesis of SELB.

Analyzing The Deal

Sobi is licensing a gout treatment called SEL-212 worldwide, except China. They are paying $75M upfront and buying $25M worth of shares at $4.62 (That's about 5.4M shares, or a dilution

Read more ...

Stock Information

Company Name: Swedish Orphan Biovit Ord
Stock Symbol: BIOVF
Market: OTC

Menu

BIOVF BIOVF Quote BIOVF Short BIOVF News BIOVF Articles BIOVF Message Board
Get BIOVF Alerts

News, Short Squeeze, Breakout and More Instantly...